QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:MCRB

Seres Therapeutics (MCRB) Price Target & Analyst Ratings

$2.33
-0.08 (-3.32%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.32
▼
$2.56
50-Day Range
$2.33
▼
$5.07
52-Week Range
$2.32
▼
$9.49
Volume
2.95 million shs
Average Volume
2.23 million shs
Market Capitalization
$298.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Seres Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$13.67
486.55% Upside
High Prediction$25.00
Average Prediction$13.67
Low Prediction$7.00
TypeCurrent
9/26/22 to 9/26/23		1 Month Ago
8/27/22 to 8/27/23		3 Months Ago
6/28/22 to 6/28/23		1 Year Ago
9/26/21 to 9/26/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.67$13.67$13.67$15.33
Predicted Upside486.55% Upside139.66% Upside139.66% Upside223.90% Upside
Get Seres Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.


MCRB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MCRB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Seres Therapeutics Stock vs. The Competition

TypeSeres TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.66
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside486.55% Upside1,373.79% Upside697.64% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/26/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$12.00+144.40%
4/28/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$12.00 ➝ $10.00+87.97%
4/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageNeutral$7.00+10.58%
3/21/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$11.00 ➝ $15.00+146.71%
3/8/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy$25.00+362.96%
12/8/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$9.00 ➝ $13.00+97.27%
(Data available from 9/26/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MCRB Price Target - Frequently Asked Questions

What is Seres Therapeutics's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Seres Therapeutics stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for MCRB. The average twelve-month price prediction for Seres Therapeutics is $13.67 with a high price target of $25.00 and a low price target of $7.00. Learn more on MCRB's analyst rating history.

Do Wall Street analysts like Seres Therapeutics more than its competitors?

Analysts like Seres Therapeutics more than other Medical companies. The consensus rating score for Seres Therapeutics is 2.80 while the average consensus rating score for medical companies is 2.66. Learn more on how MCRB compares to other companies.

Does Seres Therapeutics's stock price have much upside?

According to analysts, Seres Therapeutics's stock has a predicted upside of 138.51% based on their 12-month price targets.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:MCRB) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -